This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
4 - 6 June, 2024
Excel London Platinum Suite



At the heart of the OmniAb platform is the Biological Intelligence™ including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. OmnidAb ™ is an in vivo platform for single domain antibodies based upon a human VH scaffold. These proprietary technologies are joined with OmniDeep™, which is a suite of in silico tools. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology.

We're bringing you

  • OmniAb™: Transgenic Chickens Producing Human Heavy Chain-only Antibodies Demonstrate Robust Immune Repertoires and High-affinity Binding